MapLight Therapeutics, Inc. (MPLT) saw its stock price soar 5.11% during intraday trading on Thursday, marking a significant upward movement for the biopharmaceutical company.
The surge appears to be driven by positive analyst coverage, as Craig-Hallum initiated coverage of MapLight Therapeutics with a Buy rating and set a price target of $43. Such bullish analyst initiations often generate increased investor interest and buying activity in the stock.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments